Kyverna Therapeutics (KYTX) Proxy Filing summary

Executive summary

• Annual meeting scheduled for May 29, 2025, with virtual participation available to shareholders.

• Shareholders are encouraged to review proxy materials and vote by May 28, 2025.

Voting matters and shareholder proposals

• Election of two Class I directors, Beth Seidenberg, M.D. and Fred E. Cohen, M.D., D.Phil., to serve until the 2028 annual meeting.

• Ratification of BDO USA, P.C. as independent auditor for the fiscal year ending December 31, 2025.

• Proxies may vote on other business that arises during the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends voting in favor of both director nominees and the auditor ratification.